
FDA approved Novartis’ secukinumab (Cosentyx) 150 mg for adults with polymyalgia rheumatica who respond inadequately to corticosteroids or cannot tolerate a taper. In the Phase 3 REPLENISH trial, secukinumab doubled sustained remission rates.
FDA has issued a list of planned draft and final guidance documents for release throughout 2012.
FDA has issued a list of planned draft and final guidance documents for release throughout 2012. There are about 50 such
In biopharmaceutics and biosimilarity:
In combination products:
In CGMPs and compliance:
In labeling, packaging, and supply chain:
In regulatory filings (electronic):






